The Complix management team
Mark Vaeck has more than 25 years of experience in the biotech and pharma industry and has raised over €80 million in equity financing. In 2008 he co-founded the biopharmaceutical company Complix (Belgium) and was appointed as its CEO in May 2010.
Before that, from 2006 until 2010 he was the founding CEO of ActoGeniX (Belgium). From 2001 until 2006 he was the CEO of Ablynx (Belgium), which he co-founded in June 2001. Prior to joining Ablynx, Mark was Chief Operating Officer of Ceres Inc (US), a NASDAQ listed company that develops innovative technologies for biofuel production. From 1993 until 1998 he served as Director Business Development and thereafter as CEO of Keygene (The Netherlands). Between 1983 and 1993 he held several management positions in the biotech and pharma industry, including Director Business Development at EuroCetus (Chiron Corp.), Manager Licensing at UCB Pharma, and Manager Business Development at Plant Genetic Systems.
Mark holds a PhD in Immunology from the University of Brussels (1982).
Ignace Lasters has more than 20 years of experience in the life science industry. He has published over 60 internationally peer-reviewed articles and is named inventor on numerous patent applications. His research experience involves various aspects of biochemistry, physic-chemistry and computer modeling techniques applied to protein engineering and drug discovery.
Ignace holds a PhD in Biochemistry from the Free University of Brussels (1980). He joined the biotech industry in 1986, as head of the Computer Modeling Group in the Protein Engineering Division of PGS (now Bayer CropSciences, Ghent, Belgium), where he focused on the development of 3D modeling software to improve the functional properties of industrial enzymes. In 1991 he joined Corvas International (now Dendreon, WA, USA) and headed up a team that discovered novel anti-thrombotics based on inhibitors of enzymes in the blood coagulation cascade. In 1995 he went back to academia and spent two years at the University of Leuven (Belgium), in the laboratory of Professor Desiré Collen, the inventor of t-PA and founder of ThromboGenics. Thereafter, from 1997 onwards he worked as an independent consultant for various companies, including Innogenetics, Keygene and Genscope, focusing on structural bioinformatics, biostatistics and advanced scientific programming applications.
In 1999, Ignace co-founded Algonomics, a bioinformatics company dedicated to immunogenicity analysis and antibody engineering, and acted as its CEO/CSO until 2008, when Algonomics was acquired by Lonza.
In 2008 Ignace co-founded Complix and became its first CEO. From June 2010 Ignace assumed the roles of CSO and, more recently, CTO at Complix.
Yvonne McGrath has 14 years of biotech and pharma industry experience. Before joining Complix as CSO in May 2014, she was Head of Development at Immunocore, and before that Head of Preclinical Development and CMC. In these positions, she successfully developed and executed the late preclinical and early clinical strategy for a novel platform technology and led manufacturing and CMC strategy for a new biological entity targeting cancer. Yvonne´s previous experience includes being a Project Manager at the UK subsidiary of the German biotech company MediGene AG, and Senior Scientist at BioVex (now part of Amgen). At BioVex, she was involved in developing a viral delivery mechanism for the immunotherapeutic treatment of melanoma. Yvonne holds a PhD from the University of Wales, College of Medicine.